PASG (Passage Bio, Inc.) היקף יתרות המזומנים של החברה

Passage Bio, Inc. (PASG) has outsourced its vector production to third-party contractors to minimize risks. The cash balance reflects current liquidity, with the indicator standing at 0.02. Drug development is being conducted in collaboration with the University of Pennsylvania. However, the company faces significant investor pressure and fierce global competition within the neurotherapy sector.
פילוחים אנליטיים ודוחות נתונים של חברת passagebio.com (PASG)

This indicator captures the total volume of the company's liquid assets, determining its ability to cover operating expenses without seeking external financing. By analyzing changes in cash asset volume, an investor assesses the financial stability of Passage Bio, Inc. (PASG), which is critical for sustaining costly gene therapy developments and protecting patent barriers when creating proprietary treatment protocols.